Document:

Exhibit 4.5

 

FORM OF BROKERS WARRANT

 

THIS WARRANT AND THE SECURITIES
ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED
UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.

 

	
        Date of Issuance
	 	Void after
	 	 	 
	February [—], 2016	 	February __, 2021

 

WARRANT NO.______

 

WARRANT TO PURCHASE SHARES OF SERIES
B PREFERRED STOCK OR COMMON STOCK

 

For the purchase price of $1.25 per share
(the “Warrant Price”) the receipt and sufficiency of which is hereby acknowledged, this Warrant is issued to ________
(the “Holder”) by ATRINSIC, INC., a Delaware corporation (the “Company”).

 

1.             Purchase
of Shares.

 

(a)           Number
of Shares.  Subject to the terms and conditions set forth herein, the Holder is entitled, upon surrender of this Warrant
at the principal office of the Company (or at such other place as the Company shall notify the Holder in writing), to purchase
from the Company up to [—————] ([———————]) fully paid and
nonassessable shares (the “Shares”) of (i) prior to the Reverse Stock Split (as defined in the Certificate of Designations,
Powers, Preferences and Other Rights of Preferred Stock and Qualifications, Limitations and Restrictions for the Company’s
Series B Convertible Preferred Stock, par value $0.000001 per share (the “Series B Shares”)) the Company’s Series
B Shares and/or (ii) after the Reverse Stock Split, the Company’s common stock, par value $0.000001 per share (the “Common
Stock”).

 

(b)           Exercise
Price. The exercise price for the Series B Shares and/or the shares of Common Stock issuable pursuant to this Section 1 (the
“Shares”) shall be $1.25 per share (the “Exercise Price”). The Shares and the Exercise Price shall be subject
to adjustment pursuant to Section 9 hereof.

 

     

     

    

 

2.             Vesting;
Exercise Period.

 

(a)           Subject
to the Beneficial Ownership Cap, as defined below, this Warrant shall be immediately exercisable.

 

(b)           This
Warrant shall be exercisable, in whole or in part, during the term commencing on February [—], 2016 and ending at 5:00 p.m.,
New York time, on February [—], 2021 (the “Exercise Period”), after which time this Warrant shall become void
and of no value; provided, however, that in the event of (i) the consummation of the Company’s sale of its
Common Stock or other securities pursuant to a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”) (other than a registration statement relating either to sale of securities to employees of the Company pursuant to
its stock option, stock purchase or similar plan or a SEC Rule 145 transaction), (ii) the closing of the Company’s sale or
transfer of all or substantially all of its assets, or (iii) the closing of the acquisition of the Company by another entity (excluding
the Company’s proposed reverse merger with Protagenic Therapeutics, Inc.) by means of merger, consolidation or other transaction
or series of related transactions, resulting in the exchange of the outstanding shares of the Company’s capital stock such
that the stockholders of the Company prior to such transaction own, directly or indirectly, less than 50% of the voting power of
the surviving entity (each action in (i) through (iii), a “Corporate Transaction”), this Warrant shall, on the date
of such event, no longer be exercisable and become null and void.  In the event of a proposed transaction of the kind described
above, the Company shall notify the holder of the Warrant at least fifteen (15) days prior to the consummation of such event or
transaction and shall provide the Holder with a description of the proposed terms and conditions of such transaction, including
the amount and form of consideration to be received for each share of the Company's capital stock.

 

(c)           The
right of exercise shall be cumulative so that to the extent this Warrant is not exercised in any period to the maximum extent permissible
it shall continue to be exercisable, in whole or in part, until the earlier of the termination of the Exercise Period or the earlier
termination of this Warrant under section 2(b) hereof.

 

(d)           The
Holder of the Warrant shall be afforded the protections set forth in Section 4(j) of the Securities Purchase Agreement, as amended,
for the Offering.

 

3.             Method
of Exercise.

 

(a)           While
this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder may exercise, in whole or in part,
the purchase rights evidenced hereby. Such exercise shall be effected by:

 

(i)          a
duly executed copy of the Notice of Exercise attached hereto, to the Secretary of the Company at its principal office (or at such
other place as the Company shall notify the Holder in writing); and

 

(ii)         the
payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased, unless a cashless
exercise is being made pursuant to Section 4 below.

 

(b)           Each
exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which the
Notice of Exercise is delivered to the Company as provided in Section 3 (a) above. At such time, the person or persons in whose
name or names any certificate for the Shares shall be issuable upon such exercise as provided in Section 3(c) below shall be deemed
to have become the holder or holders of record of the Shares represented by such certificate.

 

    	2

     

    

 

(c)           As
soon as practicable after the exercise of this Warrant in whole or in part, and in any event within five (5) days thereafter, the
Company at its expense will cause to be issued in the name of, and delivered to, the Holder, or as such Holder (upon payment by
such Holder of any applicable transfer taxes) may direct:

 

(i)          a
certificate or certificates for the number of Shares to which such Holder shall be entitled, and

 

(ii)         in
case such exercise is in part only, and the Holder has surrendered the Warrant, a new warrant or warrants (dated the date hereof)
of like tenor, calling in the aggregate on the face or faces thereof for the number of Shares equal to the number of such Shares
described in this Warrant minus the number of such Shares purchased by the Holder upon all exercises made in accordance with Section
3(a) above or Section 4 below.

 

4.          Net
Exercise. In lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value of this Warrant
(or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with notice
of such election (a “Net Exercise”). A Holder who Net Exercises shall have the rights described in Sections 3(b) and
3(c) hereof, and the Company shall issue to such Holder a number of Shares computed using the following formula:

 

 

Where

 

		X =	The number of Warrant Shares to be issued to the Holder.

 

		Y =	The number of Warrant Shares purchasable under this Warrant
or, if only a portion of the Warrant is being exercised, the portion of the Warrant being cancelled (at the date of such calculation).

 

		A =	The fair market value of one (1) Share (at the date of
such calculation).

 

		B =	The Exercise Price (as adjusted to the date of such calculation).

 

For purposes of this
Section 4, the fair market value of a Share shall mean the average of the closing prices of the Shares (or equivalent shares of
Common Stock underlying this Warrant) quoted in the over-the-counter market in which the Shares (or equivalent shares of Common
Stock underlying the Warrant) are traded or the closing price quoted on any exchange or electronic securities market on which the
Shares (or equivalent shares of Common Stock underlying the Warrant) are listed, whichever is applicable, as published in The
Wall Street Journal for the thirty (30) trading days prior to the date of determination of fair market value (or such shorter
period of time during which such Shares were traded over-the-counter or on such exchange). In the event that this Warrant is exercised
pursuant to this Section 4 in connection with an initial public offering described in Section 2(b)(i) (an “Initial Public
Offering”), fair market value per Share shall be the higher of (i) the fair market value determined in the preceding sentence
or (ii) the per share offering price to the public of the Initial Public Offering. If the Shares are not traded on the over-the-counter
market, an exchange or an electronic securities market, the fair market value shall be the price per Share that the Company could
obtain from a willing buyer for Shares sold by the Company from authorized but unissued Shares, as such prices shall be determined
in good faith by the Company’s Board of Directors.

 

    	3

     

    

 

5.             Representations
and Warranties of the Company. In connection with the transactions provided for herein, the Company hereby represents and warrants
to the Holder that:

 

(a)           Organization,
Good Standing, and Qualification.  The Company is a corporation duly organized, validly existing, and in good standing
under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted.
The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on its business or properties.

 

(b)           Authorization.
Except as may be limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the enforcement
of creditors’ rights, all corporate action has been taken on the part of the Company, its officers, directors, and stockholders
necessary for the authorization, execution and delivery of this Warrant. The Company has taken all corporate action required to
make all the obligations of the Company reflected in the provisions of this Warrant the valid and enforceable obligations they
purport to be. The issuance of this Warrant will not be subject to preemptive rights of any stockholders of the Company. The Company
has authorized sufficient shares of Series B Shares and, following the Reverse Stock Split, Common Stock, to allow for the exercise
of this Warrant.

 

(c)          
Compliance with Other Instruments. The authorization, execution and delivery of the Warrant will not constitute or result
in a material default or violation of any law or regulation applicable to the Company or any material term or provision of the
Company’s current Certificate of Incorporation or bylaws, or any material agreement or instrument by which it is bound or
to which its properties or assets are subject.

 

(d)           Valid
Issuance of Common Stock. The Shares, when issued, sold, and delivered in accordance with the terms of the Warrants for the
consideration expressed therein, will be duly and validly issued, fully paid and nonassessable and, based in part upon the representations
and warranties of the Holders in this Warrant, will be issued in compliance with all applicable federal and state securities laws.

 

6.             Representations
and Warranties of the Holder. In connection with the transactions provided for herein, the Holder hereby represents and warrants
to the Company that:

 

(a)           Restricted
Securities. The Holder understands that the Securities are characterized as “restricted securities” under the federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that
under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited
circumstances. In this connection, each Holder represents that it is familiar with Rule 144, as presently in effect, as promulgated
by the SEC under the Act (“Rule 144”), and understands the resale limitations imposed thereby and by the Act.

 

    	4

     

    

 

(b)           Legends.
It is understood that the Securities may bear the following legend:

 

“THESE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED,
OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE
144 UNDER SUCH ACT.”

 

7.             State
Commissioners of Corporations. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH
THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY
PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT
FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT
ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

 

8.            
Covenants of the Company.

 

(a)           Notices
of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the purpose
of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash
dividends paid in previous quarters and stock dividends) or other distribution, the Company shall mail to the Holder, at least
ten (10) days prior to such record date, a notice specifying the date on which any such record is to be taken for the purpose of
such dividend or distribution.

 

(b)           Covenants
as to Shares. The Company covenants and agrees that all Shares that may be issued upon the exercise of the rights represented
by this Warrant will, upon issuance in accordance with the terms hereof, be validly issued and outstanding, fully paid and nonassessable,
and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that
the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient
number of Shares to provide for the exercise of the rights represented by this Warrant. If at any time during the Exercise Period
the number of authorized but unissued Shares shall not be sufficient to permit exercise of this Warrant, the Company will take
such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued Shares to such
number of Shares as shall be sufficient for such purposes.

 

    	5

     

    

 

(c)          
No Impairment. Except and to the extent waived or consented to by the Holder or as otherwise permitted under the terms hereof,
the Company will not, by amendment of its Certificate of Incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying
out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to protect
the exercise rights of the Holder against impairment.

 

9.             Adjustment
of Exercise Price and Number of Shares. The number and kind of Shares purchasable upon exercise of this Warrant and the Exercise
Price shall be subject to adjustment from time to time as follows:

 

(a)           Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the issuance but prior to the expiration of this Warrant
subdivide its Shares, by split-up or otherwise, or combine its Shares, or issue additional shares of its Series B Shares or Common
Stock as a dividend with respect to any shares of its Common Stock or Series B Shares, the number of Shares issuable on the exercise
of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately
decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price payable per share, but
the aggregate Exercise Price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the
same. Any adjustment under this Section 9(a) shall become effective at the close of business on the date the subdivision or combination
becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of
such dividend.

 

(b)           Reclassification,
Reorganization and Consolidation. In case of any reclassification, capital reorganization or change in the capital stock of
the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 9(a) above), then,
as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right
at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this
Warrant, the kind and amount of shares of stock and other securities or property receivable in connection with such reclassification,
reorganization or change by a holder of the same number and type of securities as were purchasable as Shares by the Holder immediately
prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to
the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of
stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise
Price per Share payable hereunder, provided the aggregate Exercise Price shall remain the same.

 

(c)           Notice
of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the
Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Shares or other
securities or property thereafter purchasable upon exercise of this Warrant.

 

    	6

     

    

 

10.           No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise
Price then in effect.

 

11.           No
Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder with
respect to the Shares, including (without limitation) the right to vote such Shares, receive dividends or other distributions thereon,
exercise preemptive rights or be notified of stockholder meetings, and, except as otherwise provided in this Warrant, such Holder
shall not be entitled to any stockholder notice or other communication concerning the business or affairs of the Company.

 

12.           Transfer
of Warrant. Subject to compliance with applicable federal and state securities laws and any other contractual restrictions
between the Company and the Holder contained herein, this Warrant and all rights hereunder are transferable in whole or in part
by the Holder to any person or entity upon written notice to the Company. Within a reasonable time after the Company’s receipt
of an executed Assignment Form in the form attached hereto, the transfer shall be recorded on the books of the Company upon the
surrender of this Warrant, properly endorsed, to the Company at its principal offices, and the payment to the Company of all transfer
taxes and other governmental charges imposed on such transfer. In the event of a partial transfer, the Company shall issue to the
new holders one (1) or more appropriate new warrants.

 

13.           Governing
Law. This Warrant shall be governed by and construed under the laws of the State of New York as applied to agreements among
New York residents, made and to be performed entirely within the State of New York.

 

14.           Successors
and Assigns. The terms and provisions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the
holders hereof and their respective successors and assigns.

 

15.           Titles
and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered in
construing or interpreting this Warrant.

 

16.           Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (a)
upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal
business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent
to the respective parties at the following addresses (or at such other addresses as shall be specified by notice given in accordance
with this Section 16):

 

    	7

     

    

 

If to the Company:

 

ATRINSIC, INC.

149 5th Avenue, Suite 500,

New York, NY 10010

 

If to Holder:

 

At the addresses shown on the signature pages hereto.

 

17.           Assumption
of Warrant. If at any time while this Warrant, or any portion thereof, is outstanding and unexpired there shall be a Corporate
Transaction, then, as a part of such transaction, lawful provision shall be made so that the Holder shall thereafter be entitled
to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price then in effect,
the number of shares of stock or other securities or property of the successor corporation resulting from Corporate Transaction
which a holder of the shares deliverable upon exercise of this Warrant would have been entitled to receive in such Corporate Transaction
if this Warrant had been exercised immediately before such Corporate Transaction, all subject to further adjustment as provided
in this Section 16; and, in any such case, appropriate adjustment (as determined by the Company’s Board of Directors) shall
be made in the application of the provisions herein set forth with respect to the rights and interests thereafter of the Holder
to the end that the provisions set forth herein (including provisions with respect to changes in and other adjustments of the number
of Shares the Holder is entitled to purchase) shall thereafter by applicable, as nearly as possible, in relation to any Shares
or other securities or other property thereafter deliverable upon the exercise of this Warrant.

 

18.           Finder’s
Fee. Each party represents that it neither is or will be obligated for any finder’s fee or commission in connection with
this transaction. The Holder agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation
in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted liability) for
which the Holder or any of its officers, partners, employees or representatives is responsible. The Company agrees to indemnify
and hold harmless the Holder from any liability for any commission or compensation in the nature of a finder’s fee (and the
costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees
or representatives is responsible.

 

19.           Expenses.
If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be
entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party
may be entitled.

 

20.           Entire
Agreement; Amendments and Waivers. This Warrant and any other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. Nonetheless, any term of this Warrant
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively), with the written consent of the Company and the Holder; or if this Warrant has been assigned
in part, by the holders or rights to purchase a majority of the Shares originally issuable pursuant to this Warrant.

 

    	8

     

    

 

21.           Severability.
If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall be excluded from this Warrant
and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms

 

22.           Limitation
on Beneficial Ownership. Except as provided otherwise in this Section, the number of Shares that may be acquired upon the exercise
of this Warrant shall be limited to the extent necessary to ensure that, after giving effect to such exercise, the number of shares
of Common Stock then beneficially owned by the Holder and its Affiliates and any other persons or entities whose beneficial ownership
of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”) (including shares held by any “group” of which the Holder is a member,
but, for avoidance of doubt, excluding shares of Common Stock issuable upon conversion or exercise of securities or rights to acquire
securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) does
not exceed 9.99% of the total number of shares of Common Stock of the Company issued and outstanding immediately after giving effect
to such conversion (or deemed conversion for voting purposes) (the “Beneficial Ownership Cap”). For purposes hereof,
“group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities
and Exchange Commission, and the percentage held by the Holder shall be determined in a manner consistent with the provisions of
Section 13(d) of the Exchange Act. As used herein, the term “Affiliate” means any person or entity that, directly or
indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity,
as such terms are used in and construed under Rule 144 under the Securities Act. With respect to the Holder, any investment fund
or managed account that is managed on a discretionary basis by the same investment manager as the Holder will be deemed to be an
Affiliate of the Holder. This paragraph shall be construed and administered in such manner as shall be consistent with the intent
of the first sentence of this paragraph. Any provision hereof which would require a result that is not consistent with such intent
shall be deemed severed herefrom and of no force or effect with respect to the exercise contemplated by this Warrant.

 

    	9

     

    

 

For purposes of the foregoing, the number
of shares of Common Stock beneficially owned by the Holder and its affiliates shall include the number of shares of Common Stock
issuable upon exercise of the Warrants, but shall exclude the number of shares of Common Stock which would be issuable upon (A)
conversion of the remaining, nonconverted shares of Series B Shares beneficially owned by the Holder or any of its affiliates and
(B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without
limitation, any notes or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained in this
Section beneficially owned by the Holder or any of its affiliates. Except as set forth in the preceding sentence, for purposes
of this Section 22, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. For purposes
of this Section, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding
shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q, or Form 8-K, as the case may be,
(2) a more recent public announcement by the Company, or (3) any other notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding. For any reason at any time, upon the written request of any the Holder, the Company
shall within two (2) business days following the receipt of such notice, confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the exercise of the Warrant (or portion thereof being exercised) by the Holder and its Affiliates since the date
as of which such number of outstanding shares of Common Stock was reported.

 

The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section to correct this Section
(or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation.

 

    	10

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Warrant as of the date first written above.

 

	 	ATRINSIC, INC.
	 	 	 
	 	By: 	                   
	 	 	Garo H. Armen
	 	 	Chairman

 

	 	Address:	162 5th Avenue, Suite 900
	 	 	New York, NY 10010

 

ACKNOWLEDGED AND AGREED:

 

HOLDER

 

	 	 
	Signature	 

 

Address

 

	 	 
	 	 
	 	 
	 	 
	 	 

 

    	11

     

    

 

NOTICE
OF EXERCISE

 

ATRINSIC, INC.

Attention: Corporate Secretary

 

The undersigned hereby
elects to purchase, pursuant to the provisions of the Warrant, as follows:

 

		 ̈	_____________ Shares pursuant to the terms of the attached Warrant, and tenders herewith payment
in cash of the Exercise Price of such Shares in full, together with all applicable transfer taxes, if any.

 

		 ̈	Net Exercise the attached Warrant with respect to __________ Shares.

 

The undersigned hereby
represents and warrants that Representations and Warranties in Section 7 hereof are true and correct as of the date hereof.

 

	 	HOLDER:
	 	 	 
	Date:___________________	By: 	                       

 

	 	Address:	 
	 	 	 
	 	 	 

 

	Name in which shares should be registered:	 
	 	 
	 	 

 

    	12

     

    

 

ASSIGNMENT
FORM

 

(To assign the foregoing Warrant,
execute this form and supply required information. Do not use this form to purchase shares.)

 

For
Value Received, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please Print)
	 	 
	Address:	 
	 	(Please Print)

 

Dated: _________________

 

	Holder’s	 	 
	Signature:	 	 
	 	 	 
	Holder’s	 	 
	Address:	 	 

 

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant. Officers of corporations and those acting in a fiduciary
or other representative capacity should provide proper evidence of authority to assign the foregoing Warrant.

 

    	13Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of ____________, 2016, is by and among Atrinsic, Inc., a
Delaware corporation (the “Company”), and each of the investors listed on the Buyer signature pages attached
hereto (individually, a “Buyer” and collectively, the “Buyers”).

 

RECITALS

 

A.            Each
Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, that number of
shares of Series B Preferred Stock (which shall collectively be referred to herein as the “Series B Shares”)
set forth on the respective Buyer’s signature page convertible in accordance with the terms of the Series B Shares into shares
of common stock (“Common Stock”) of the Company (such shares of Common Stock, the “Underlying Common
Stock”). The minimum number of Series B Shares to be sold in this placement shall be 2,680,000 (the “Minimum
Offering”) and the maximum number shall be 3,200,000 (the “Maximum Offering”). The Company may, in
its discretion, increase the Maximum Offering by up to 1,200,000 Series B Shares.

 

B.            The
Series B Shares and the Underlying Common Stock are collectively referred to herein as the “Securities.”

 

C.            Simultaneously
with the Initial Closing (defined herein) Protagenic Acquisition Corp. (“Acquisition Subsidiary”) shall merge with
and into Protagenic Therapeutics, Inc. (“PTI”), with PTI remaining as the surviving entity after the merger
(the “Merger”), whereby the stockholders of PTI will receive Series B Shares, in exchange for all of the capital
stock of PTI.

 

D.            After
the Merger, the Company shall enact a reverse stock split (the “Reverse Stock Split”) whereby every 15,463.7183 shares
of outstanding Common Stock shall be exchanged for one share of new Common Stock.

 

E.            
Upon the completion of the Reverse Stock Split, each Series B Share shall automatically convert into one share (on a post-Reverse
Stock Split basis) of the Company’s Common Stock, subject to certain provisions of the Certificate of Designations, Preferences
and Rights of Series B Preferred Stock governing the Series B Shares (the “Certificate of Designations”).

 

F.            Contemporaneously
with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement,
substantially in the form attached hereto as Exhibit 1 (the “Registration Rights Agreement”), pursuant to which,
among other things, the Company will agree to provide certain rights to register with the U.S. Securities and Exchange Commission
under the 1933 Act and the rules and regulations promulgated thereunder and applicable state securities laws shares of Common Stock
underlying the Series B Shares sold pursuant to this Agreement and Common Stock underlying the Placement Agent Warrants (as defined
herein) .

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and each Buyer hereby agree as follows:

 

     

     

    

 

1.            PURCHASE
AND SALE OF SERIES B SHARES.

 

(a)           Purchase
of Series B Shares. Subject to the satisfaction (or waiver) of the conditions set forth in Section 6 below, the Company shall
issue and sell to each Buyer, and each Buyer severally, but not jointly, shall purchase from the Company on each Closing Date (as
defined below), the number of Series B Shares as is set forth opposite such Buyer’s name on the respective Buyer’s
signature page. Each Buyer introduced to the Company by the Placement Agent shall (and any Buyer that was not introduced to the
Company by the Placement Agent shall) deliver on or before the applicable Closing the Purchase Price in full to Delaware Trust
Company (the “Escrow Agent”) by check to the address listed below or via wire transfer of immediately available
funds pursuant to the wire instructions below, unless other provisions have been agreed upon with the Buyer. Each Buyer understands
that the applicable Purchase Price (defined below) will be held in escrow until the applicable Closing on the Series B Shares (as
such terms are defined below) has occurred, and that such amount will be returned to such Buyer, without interest, if (i) the closing
of a Minimum Offering does not occur on or before February 29, 2016, which date may be extended to April 15, 2016, in the discretion
of the Company, (ii) such Buyer’s purchase is rejected by the Company in whole or in part, (iii) such Buyer revokes such
purchase prior to the Closing Date, (iv) the Company terminates the offering of the Series B Shares, or (v) a court of competent
jurisdiction issues a final and non-appealable judgment, order, decree or award ordering the escrow agent to deliver the Purchase
Price.

 

Address for Payment by
Check:

Delaware Trust Company

2711 Centerville Road

One Little Falls Centre

Wilmington, DE 19808

Attention: Alan R.
Halpern

Reference: Atrinsic,
Inc. Escrow #79-2579 [Insert Name of Buyer]

 

Wire Instructions:

PNC Bank

300 Delaware Avenue

Wilmington DE 19899

ABA# 031100089

SWIFT Code: PNCCUS33

Account Name: Delaware
Trust Company

Account Number:
5605012373

Reference:
Atrinsic, Inc. Escrow #79-2579 [Insert Name of Buyer]

 

(b)           Purchase
Price. The aggregate purchase price for the Series B Shares to be purchased by each Buyer (the “Purchase Price”)
shall be the amount set forth opposite such Buyer’s name on the Schedule of Buyers which shall be equal to the amount of
$1.25 per Series B Share. 

 

(c)          Closing.

 

		(i)	The initial closing (the “Initial Closing”)
of the purchase of the Series B Shares by the Buyers shall occur at the offices of Sanders Ortoli Vaughn-Flam Rosenstadt LLP (“SOVR”),
501 Madison Avenue, New York, NY 10022. The date and time of the Initial Closing (the “Initial Closing Date”)
shall be time and date on which the closing conditions set forth in Section 6 below are satisfied or waived (or such later date
as is mutually agreed to by the Company and each Buyer) provided that such date shall not be later than 5:00 pm, New York time,
on February 29, 2016, or April 15, 2016, if the date for the Initial Closing is extended by the Company. A minimum of 2,680,000
Series B Shares must be sold at the Initial Closing. In the event there is more than one closing, as described in Section 1(c)(ii)
below, the term “Closing” shall apply to each such closing unless otherwise specified and the term “Closing
Date” shall apply to each such closing date unless otherwise specified. As used in this Agreement, “Business
Day” means any day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required by law to remain closed.

 

    	 	- 2 -	 

     

    

 

		(ii)	After the Initial Closing, the Company may sell, in
one or more additional Closings (an “Additional Closing”) on the same terms and conditions as those contained
in this Agreement (such securities sold, “Additional Securities”), to one or more Buyers (each, an “Additional
Buyer,” and, collectively, the “Additional Buyers”), provided that (i) any such sale is consummated
on or prior to the earlier of ninety (90) days from the date hereof or the effective date of the Reverse Stock Split and (ii)
each Additional Buyer shall become a party to the Transaction Documents, as defined below, by executing and delivering either
an applicable adoption agreement, a counterpart signature page to each of the Transaction Documents.

 

		(iii)	Notwithstanding the foregoing, prior to the applicable
Closing with respect to certain Series B Shares for the funds by the Buyer held in escrow, the Company may, in its sole discretion,
terminate the offering of Series B Shares pursuant to this Agreement, in whole or in part, by providing notice to the applicable
Buyer(s) in accordance with Section 8(f) of this Agreement. In such case, the Company and the Company’s placement agent
shall jointly notify the Escrow Agent of such rejection and the Escrow Agent shall refund the Purchase Price (without interest
and deduction) corresponding to the rejected Series B Shares no more than seven (7) business days following receipt by the Escrow
Agent of such notice.

 

(d)           Form
of Payment; Deliveries. On each Closing Date, each Buyer purchasing Series B Shares at such Closing shall pay its respective
Purchase Price to the Company. On each Closing Date, the Company shall deliver to the transfer agent of the Company (the “Transfer
Agent”) written instructions authorizing the Transfer Agent to enter the issuance of the Series B Shares sold hereunder
in the books of the Company in the name of Buyer and in the amount set out opposite its name on the respective Buyer’s signature
page hereto.

 

2.           BUYER’S
REPRESENTATIONS AND WARRANTIES.

 

Each Buyer, severally
and not jointly, represents and warrants to the Company with respect to only itself that:

 

(a)           Organization;
Authority. Such Buyer, if an entity, is duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by this
Agreement and otherwise to carry out its obligations hereunder and thereunder.

 

    	 	- 3 -	 

     

    

 

(b)           Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of such Buyer and constitutes
the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance with their respective terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’
rights and remedies.

 

(c)           No
Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the consummation by such Buyer of the
transactions contemplated hereby will not (i) result in a violation of the organizational documents of such Buyer, (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such
Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and
state securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults,
rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect
on the ability of such Buyer to perform its obligations hereunder.

 

(d)           Own
Account. Such Buyer understands that (i) the Securities are “restricted securities” and that the offer and sale
of the Securities have not been registered under the Securities Act of 1933, as amended (the “1933 Act”) or
any applicable state securities law and (ii) the Securities must be held indefinitely unless a subsequent disposition thereof is
registered under the Securities Act or is exempt from such registration. Such Buyer is acquiring the Securities as principal for
its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the
1933 Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of
the 1933 Act or any applicable state securities law and has no direct or indirect arrangement or understanding with any other Persons
regarding the distribution of such Securities (this representation and warranty not limiting such Buyer’s right to sell the
Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws)
in violation of the 1933 Act or any applicable state securities law. Such Buyer is acquiring the Securities hereunder in the ordinary
course of its business.

 

(e)           Buyer
Status. At the time such Buyer was offered the Securities, it was, and at the date hereof it: (i) is either (A) an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the 1933 Act or (B) a “qualified institutional
buyer” as defined in Rule 144A(a) under the 1933 Act or (ii) is not a “U.S. Person” (as defined in Regulation
S promulgated under the 1933 Act). If such Buyer is not a U.S. Person, such Buyer further represents and warrants that (1) such
Buyer has not subscribed for the Series B Shares for the account of any Person who is a U.S. Person, (2) the offer and sale of
the Series B Shares to such Buyer constitute an “Offshore Transaction” (as defined in Rule 902 promulgated under the
1933 Act), and (3) such Buyer will not resell the Securities, other than in accordance with this Agreement, the Transaction Documents,
the provisions of Regulation S promulgated under the 1933 Act (Rules 901 through 905), pursuant to registration under the 1933
Act or pursuant to any other available exemption from registration. Such Buyer further agrees that it will not take any action
that could have an adverse effect on the availability of the exemption from registration provided, in the case of a Buyer covered
by clause (i) above, by Regulation D promulgated under the 1933 Act or, in the case of a Buyer covered by clause (ii) above, by
Regulation S promulgated under the 1933 Act, with respect to the offer and sale of the Series B Shares. Such Buyer is not required
to be registered as a broker-dealer under Section 15 of the Securities Exchange Act of 1934 (the “1934 Act”),
or a member of the Financial Industry Regulatory Authority, Inc. or an entity engaged in the business of being a broker dealer.
Such Buyer is not affiliated with any broker dealer registered under Section 15(a) of the 1934 Act, or a member of the Financial
Industry Regulatory Authority, Inc. or an entity engaged in the business of being a broker dealer.

 

    	 	- 4 -	 

     

    

 

(f)            Experience
of Such Buyer. Such Buyer, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities
and has so evaluated the merits and risks of such investment. Such Buyer is able to bear the economic risk of an investment in
the Securities and is able to afford a complete loss of such investment. Such Buyer understands that nothing in the Agreement or
any other materials presented to the Buyer in connection with the purchase and sale of the Securities constitutes legal, tax or
investment advice. Such Buyer acknowledges that it must rely on legal, tax and investment advisors of its own choosing in connection
with its purchase of the Securities.

 

(g)           General
Solicitation. Such Buyer is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio, disseminated
over the Internet or presented at any seminar or any other general solicitation or general advertisement.

 

(h)           Independent
Investigation. Such Buyer, in acquiring the Securities, has relied solely upon an independent investigation made by such Buyer
and his or her representatives, if any. Prior to the date hereof, such Buyer has been given the opportunity to ask questions of,
and receive answers from, representatives of the Company and the Subsidiary regarding the Company’s and the Subsidiary’s
management, finances, and business. Such Buyer also has access to or has received the SEC Documents and has carefully reviewed
the SEC Documents, including the risk factor disclosure contained therein relating to the high degree of risk involved in investing
in the Company’s securities, and is knowledgeable about the affairs of the Company and the Subsidiary. Such Buyer further
acknowledges the additional risks associated with the transactions contemplated by this Agreement as set forth on the Schedule
of Additional Risk Factors attached hereto. Neither such inquiries nor any other diligence investigation conducted by such Buyer
or any of its advisors or representatives shall modify, amend or effect such Buyer’s right to rely upon the Company’s
representations and warranties and covenants contained herein or in the Transaction Documents. As used in this Agreement, “SEC
Documents” means all reports, schedules, forms, statements and other documents, including the exhibits thereto and documents
incorporated by reference therein, filed by the Company pursuant to the 1933 Act and the 1934 Act, including pursuant to Section
13(a) or 15(d) thereof, since January 1, 2013.

 

(i)            No
Government Recommendation or Approval. Such Buyer understands that no United States federal or state agency, or similar agency
of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase
of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed
the merits of the offering of the Securities.

 

(j)            No
Intent to Effect a Change of Control. Apart from assisting in the completion of the Merger, such Buyer has no present intent
to effect a “change of control” of the Company as such term is understood under the rules promulgated pursuant to Section
13(d) of the 1934 Act.

 

(k)           Section
13(d)(3) of 1934 Act. The several Buyers shall not constitute a “group” within the meaning of Section 13(d)(3)
of the 1934 Act and the rules and regulations promulgated thereunder.

 

(l)            Former
Shell Company. Such Buyer acknowledges and understands that the Company was formerly a “shell company” as defined
in Rule 12b-2 under the 1934 Act.

 

(m)          Receipt
of Documents. Such Buyer acknowledges that it has received (i) a draft of the Agreement and Plan of Merger and Reorganization
(the “Merger Agreement”) that will govern the Merger and (ii) a copy of Investor Term Sheet, the Securities
Purchase Agreement, the Registration Rights Agreement and other documents, which, among other matters, discusses the business of
PTI, PTI’s corporate structure and the proposed capitalization table of the Company after the Offering and the Merger (the
“Transaction Documents”).

 

    	 	- 5 -	 

     

    

 

3.            REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.

 

Except as set forth
under the corresponding section of the disclosure schedules delivered to each Buyer concurrently herewith (the “Disclosure
Schedules”), which Disclosure Schedules shall be deemed a part hereof, and except as otherwise described in the SEC Documents
or in the Disclosure Schedules, the Company represents and warrants to each of the Buyers that:

 

(a)           Organization,
Qualification and Corporate Power. Each of the Company and Acquisition Subsidiary is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware. Each of the Company and the Acquisition Subsidiary is duly
qualified to conduct business and is in good standing under the laws of each jurisdiction in which the nature of its businesses
or the ownership or leasing of its properties requires such qualification, except where the failure to be so qualified or in good
standing would not have a Company Material Adverse Effect (as defined below). Each of the Company and the Acquisition Subsidiary
has all requisite corporate power and authority to carry on the businesses in which it is engaged and to own and use the properties
owned and used by it. For purposes of this Agreement, “Company Material Adverse Effect” means a material adverse effect
on the assets, business, condition (financial or otherwise), results of operations or future prospects of the Company and its Subsidiaries,
taken as a whole.

 

(b)          Capitalization.
The authorized capital stock of the Company consists of:

 

(i)          100,000,000,000
shares of Common Stock, of which 400,000,000 shares were issued and outstanding as of the date of this Agreement; and

 

(ii)         5,000,000,000
shares of preferred stock, par value $0.000001 per share, of which eighteen million (18,000,000) are designated as Series B Shares
(of which 297,468 Series B Shares are issued and outstanding).

 

The Common Stock is presently
eligible for quotation and trading on the OTC Pink operated by OTC Markets Group SEE Paragraph 4(b) and is not subject to any notice
of suspension or delisting. The Common Stock is registered under Section 12(g) of the Exchange Act. The Company is required to
file periodic reports with the SEC pursuant to the provisions of Section 13(a) of the Exchange Act. All of the issued and outstanding
shares of Common Stock are duly authorized, validly issued, fully paid, nonassessable and free of all preemptive rights. Except
as contemplated by the Transaction Documents , there are no outstanding or authorized options, warrants, rights, agreements or
commitments to which the Company is a party or which are binding upon the Company providing for the issuance or redemption of any
of its capital stock. There are no outstanding or authorized stock appreciation, phantom stock or similar rights with respect to
the Company. Excluding an agreement that will come into effect at the time of the Initial Closing pursuant to which certain holders
of the Company’s securities will agree to vote for the board directors and to enact the Reverse Stock Split, there are no
agreements to which the Company is a party or by which it is bound with respect to the voting (including without limitation voting
trusts or proxies), registration under the Securities Act, or sale or transfer (including without limitation agreements relating
to pre-emptive rights, rights of first refusal, co-sale rights or “drag-along” rights) of any securities of the Company.
There are no agreements among other parties, to which the Company is not a party and by which it is not bound, with respect to
the voting (including without limitation voting trusts or proxies) or sale or transfer (including without limitation agreements
relating to rights of first refusal, co-sale rights or “drag-along” rights) of any securities of the Company. All of
the issued and outstanding shares of Common Stock were issued in compliance with applicable federal and state securities laws.

 

    	 	- 6 -	 

     

    

 

(c)           Authorization
of Transaction. The Company has all requisite power and authority to execute and deliver this Agreement and to perform its
obligations hereunder and thereunder. The execution and delivery by the Company of the Transaction Documents and the consummation
by the Company of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate
action on the part of the Company. This Agreement has been duly and validly executed and delivered by the Company and constitutes
a valid and binding obligation of the Company, enforceable against them in accordance with its terms.

 

(d)           Noncontravention.
Neither the execution and delivery by the Company of this Agreement, nor the consummation by the Company of the transactions contemplated
hereby, will (a) conflict with or violate any provision of the articles or certificate of incorporation or bylaws of the Company,
(b) require on the part of the Company any filing with, or permit, authorization, consent or approval of, any Governmental
Entity, (c) conflict with, result in breach of, constitute (with or without due notice or lapse of time or both) a default
under, result in the acceleration of obligations under, create in any Party any right to terminate, modify or cancel, or require
any notice, consent or waiver under, any contract or instrument to which the Company is a party or by which either is bound or
to which any of their assets are subject, (d) result in the imposition of any Security Interest upon any assets of the Company
or (e) violate any order, writ, injunction, decree, statute, rule or regulation applicable to the Company or any of their
properties or assets.

 

(e)           Subsidiaries.
Company has no Subsidiaries other than the Acquisition Subsidiary and MomSpot. Each of the Acquisition Subsidiary and MomSpot is
a corporation, in the case of Acquisition Subsidiary, and a limited liability company, in the case of MomSpot, duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization. 

 

(f)           Exchange
Act Reports. The SEC Documents complied in all material respects with the requirements of the Exchange Act and the rules and
regulations thereunder when filed. As of the date hereof, there are no outstanding or unresolved comments in comment letters received
from the staff of the SEC with respect to any of the SEC Documents. As of their respective dates, the SEC Documents did not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading.

 

(g)          Compliance
with Laws. Each of the Company and the Acquisition Subsidiary:

 

(i)          and
the conduct and operations of their respective businesses, are in compliance with each applicable law (including rules and regulations
thereunder) of any federal, state, local or foreign government, or any Governmental Entity, except for any violations or defaults
that, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect;

 

(ii)         has
complied with all federal and state securities laws and regulations, including being current in all of its reporting obligations
under such federal and state securities laws and regulations;

 

(iii)        has
not, and to the knowledge of the Company, the past and present officers, directors and Affiliates of the Company have not, been
the subject of, nor does any officer or director of the Company have any reason to believe that Company or any of its officers,
directors or Affiliates will be the subject of, any civil or criminal proceeding or investigation by any federal or state agency
alleging a violation of securities laws;

 

    	 	- 7 -	 

     

    

 

(iv)        since
July 2, 2014, has not been the subject of any voluntary or involuntary bankruptcy proceeding, nor has it been a party to any material
litigation;

 

(v)         has
not, and to the knowledge of the Company, the past and present officers, directors and Affiliates have not, been the subject of,
nor does any officer or director of the Company have any reason to believe that the Company or any of its officers, directors or
affiliates will be the subject of, any civil, criminal or administrative investigation or proceeding brought by any federal or
state agency having regulatory authority over such entity or person; and

 

(vi)        does
not have any liabilities, contingent or otherwise other than those set out in the SEC Documents, and at the Initial Closing will
not have any liabilities, contingent or otherwise, including but not limited to notes payable and accounts payable, other than
those set out in the SEC Documents, and is not a party to any executory agreements.

 

(h)          Absence
of Certain Changes. Except as set out in the SEC Documents, since the date of the balance sheet contained in the most recent
SEC Document with a balance sheet, (a) there has occurred no event or development which, individually or in the aggregate, has
had, or could reasonably be expected to have in the future, a Company Material Adverse Effect and (b) neither the Company nor the
Acquisition Subsidiary has taken any of the actions, except as set out in the SEC Documents, set forth below:

 

(i)          issue
or sell, or redeem or repurchase, any stock or other securities of the Company or any rights, warrants or options to acquire any
such stock or other securities, except as contemplated by, and in connection with, this placement and the Merger;

 

(ii)         split,
combine or reclassify any shares of its capital stock; declare, set aside or pay any dividend or other distribution (whether in
cash, stock or property or any combination thereof) in respect of its capital stock, except as contemplated by, and in connection
with, this Agreement;

 

(iii)        create,
incur or assume any indebtedness (including obligations in respect of capital leases); assume, guarantee, endorse or otherwise
become liable or responsible (whether directly, contingently or otherwise) for the obligations of any other person or entity; or
make any loans, advances or capital contributions to, or investments in, any other person or entity;

 

(iv)        enter
into, adopt or amend any Employee Benefit Plan or any employment or severance agreement or arrangement or (except for normal increases
in the Ordinary Course of Business for employees who are not Affiliates) increase in any manner the compensation or fringe benefits
of, or materially modify the employment terms of, its directors, officers or employees, generally or individually, or pay any bonus
or other benefit to its directors, officers or employees, except for the adoption of the 2006 Plan in connection with the Merger;

 

    	 	- 8 -	 

     

    

 

(v)         mortgage
or pledge any of its property or assets or subject any such property or assets to any Security Interest;

 

(vi)        amend
its charter, by-laws or other organizational documents; 

 

(vii)       change
in any material respect its accounting methods, principles or practices, except insofar as may be required by a generally applicable
change in GAAP;

 

(viii)      enter
into, amend, terminate, take or omit to take any action that would constitute a violation of or default under, or waive any rights
under, any material contract or agreement;

 

(ix)         institute
or settle any Legal Proceeding;

 

(x)          take
any action or fail to take any action permitted by this Agreement with the knowledge that such action or failure to take action
would result in (i) any of the representations and warranties of the Company and/or the Acquisition Subsidiary set forth in this
Agreement becoming untrue in any material respect or (ii) any of the conditions to the Merger set forth in Article V not being
satisfied; or

 

(xi)         agree
in writing or otherwise to take any of the foregoing actions.

 

(i)            Litigation.
Except as disclosed in the SEC Documents and the Transaction Documents, as of the date of this Agreement, there is no Legal Proceeding
which is pending or, to the Company’s knowledge, threatened against the Company or any Subsidiary of the Company. 

 

(j)            Undisclosed
Liabilities. None of the Company and its Subsidiaries has any liabilities other than those set out in the SEC Documents.

 

(k)           Tax
Matters. 

 

 (i)          Each
of the Company and the Acquisition Subsidiary has filed all Tax Returns that it was required to file, and all such Tax Returns
were complete and accurate in all material respects. Neither the Company nor any Subsidiary is or has ever been a member of a group
of corporations with which it has filed (or been required to file) consolidated, combined or unitary Tax Returns, other than a
group of which only the Company and the Subsidiaries are or were members. Each of the Company and the Company Subsidiaries has
paid on a timely basis all Taxes that were due and payable. Any unpaid Taxes of the Company and the Company Subsidiaries for tax
periods through the date of the balance sheet contained in the most recent Company Report do not exceed the accruals and reserves
for Taxes (excluding accruals and reserves for deferred Taxes established to reflect timing differences between book and Tax income)
set forth on such balance sheet. Except as set out in the SEC Documents, neither the Company nor any Company Subsidiary has any
actual or potential liability for any Tax obligation of any taxpayer (including without limitation any affiliated group of corporations
or other entities that included the Company or any Company Subsidiary during a prior period) other than the Company and the Company
Subsidiaries. All Taxes that the Company or any Company Subsidiary is or was required by law to withhold or collect have been duly
withheld or collected and, to the extent required, have been paid to the proper Governmental Entity.

 

    	 	- 9 -	 

     

    

 

(ii)         No
examination or audit of any Tax Return of the Company or any Company Subsidiary by any Governmental Entity is currently in progress
or, to the knowledge of the Company, threatened or contemplated. Except as set out in the SEC Documents, neither the Company nor
any Company Subsidiary has been informed by any jurisdiction that the jurisdiction believes that the Company or such Subsidiary
was required to file any Tax Return that was not filed. Neither the Company nor any Company Subsidiary has waived any statute of
limitations with respect to Taxes or agreed to an extension of time with respect to a Tax assessment or deficiency.

 

(iii)        Neither
the Company nor any Company Subsidiary: (i) is a “consenting corporation” within the meaning of Section 341(f)
of the Code, and none of the assets of the Company or the Company Subsidiaries are subject to an election under Section 341(f)
of the Code; (ii) has been a United States real property holding corporation within the meaning of Section 897(c)(2)
of the Code during the applicable period specified in Section 897(c)(l)(A)(ii) of the Code; (iii) has made any payments,
is obligated to make any payments, or is a party to any agreement that could obligate it to make any payments that may be treated
as an “excess parachute payment” under Section 280G of the Code; (iv) has any actual or potential liability
for any Taxes of any person (other than the Company and its Subsidiaries) under Treasury Regulation Section 1.1502-6 (or any
similar provision of federal, state, local, or foreign law), or as a transferee or successor, by contract, or otherwise; or (v) is
or has been required to make a basis reduction pursuant to Treasury Regulation Section 1.1502-20(b) or Treasury Regulation
Section 1.337(d)-2(b).

 

(iv)        None
of the assets of the Company or any Subsidiary: (i) is property that is required to be treated as being owned by any other
person pursuant to the provisions of former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended, and in effect
immediately prior to the enactment of the Tax Reform Act of 1986; (ii) is “tax-exempt use property” within the
meaning of Section 168(h) of the Code; or (iii) directly or indirectly secures any debt the interest on which is tax
exempt under Section 103(a) of the Code.

 

(v)         Neither
the Company nor any Subsidiary has undergone a change in its method of accounting resulting in an adjustment to its taxable income
pursuant to Section 481 of the Code.

 

(vi)        No
state or federal “net operating loss” of the Company determined as of the Closing Date is subject to limitation on
its use pursuant to Section 382 of the Code or comparable provisions of state law as a result of any “ownership change”
within the meaning of Section 382(g) of the Code or comparable provisions of any state law occurring prior to the Closing
Date. 

 

(l)           Owned
Real Property. Neither the Company nor any Company Subsidiary owns any real property. 

 

(m)         Employees.

 

(i)          The
SEC Documents contain all material information concerning the employees of Company.

 

    	 	- 10 -	 

     

    

 

(ii)         Neither
the Company nor any Company Subsidiary is a party to or bound by any collective bargaining agreement, nor have any of them experienced
any strikes, grievances, claims of unfair labor practices or other collective bargaining disputes. The Company has no knowledge
of any organizational effort made or threatened, either currently or since the date of organization of the Company, by or on behalf
of any labor union with respect to employees of the Company or any Company Subsidiary.

 

(n)          Employee
Benefits. 

 

(i)          There
are no Employee Benefit Plans that are currently contributed to, by the Parent, any Parent Subsidiary or any entity which is, or
at any applicable time was, a member of (1) a controlled group of corporations (as defined in Section 414(b) of the Code),
(2) a group of trades or businesses under common control (as defined in Section 414(c) of the Code), or (3) an affiliated
service group (as defined under Section 414(m) of the Code or the regulations under Section 414(o) of the Code), any
of which includes or included the Company (an “ERISA Affiliate”). 

 

(ii)         Neither
the Company, any Company Subsidiary, nor any ERISA Affiliate has ever maintained an Employee Benefit Plan subject to Section 412
of the Code or Title IV of ERISA.

 

(iii)        At
no time has the Company, any Company Subsidiary or any ERISA Affiliate been obligated to contribute to any “multiemployer
plan” (as defined in Section 4001(a)(3) of ERISA).

 

(iv)        No
Employee Benefit Plan is funded by, associated with or related to a “voluntary employee’s beneficiary association”
within the meaning of Section 501(c)(9) of the Code.

 

(o)          Environmental
Matters. 

 

(i)          Each
of the Company and the Company Subsidiaries has complied with all applicable Environmental Laws, except for violations of Environmental
Laws that, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse
Effect. There is no pending or, to the knowledge of the Company, threatened civil or criminal litigation, written notice of violation,
formal administrative proceeding, or investigation, inquiry or information request by any Governmental Entity, relating to any
Environmental Law involving the Company or any Company Subsidiary. 

 

(ii)         There
are no documents (whether in hard copy or electronic form) that contain any environmental reports, investigations and audits relating
to premises currently or previously owned or operated by the Company or a Company Subsidiary (whether conducted by or on behalf
of the Company or a Company Subsidiary or a third party, and whether done at the initiative of the Company or a Company Subsidiary
or directed by a Governmental Entity or other third party) which were issued or conducted during the past five years and which
the Company has possession of or access to. 

 

    	 	- 11 -	 

     

    

 

(iii)        The
Company is not aware of any material environmental liability of any solid or hazardous waste transporter or treatment, storage
or disposal facility that has been used by the Company or any Company Subsidiary.

 

(p)           Permits.
There are no permits, licenses, registrations, certificates, orders or approvals from any Governmental Entity (including without
limitation those issued or required under Environmental Laws and those relating to the occupancy or use of owned or leased real
property) (“Company Permits”) issued to or held by the Company or any Company Subsidiary. Such listed Permits are the
only Company Permits that are required for the Company and the Company Subsidiaries to conduct their respective businesses as presently
conducted. Each such Company Permit is in full force and effect and, to the knowledge of the Company, no suspension or cancellation
of such Company Permit is threatened and there is no basis for believing that such Company Permit will not be renewable upon expiration.
Each such Company Permit will continue in full force and effect immediately following the Closing.

 

(q)           Duty
to Make Inquiry. To the extent that any of the representations or warranties in this Article III are qualified by “knowledge”
or “belief,” Company represents and warrants that it has made due and reasonable inquiry and investigation concerning
the matters to which such representations and warranties relate, including, but not limited to, diligent inquiry by its directors,
officers and key personnel.

 

(r)            No
Disqualification Events. None of the Company, nor, to the knowledge of the Company, any of its predecessors, any affiliated
issuer, any director, executive officer, other officer of the Company participating in the Offering or the Merger, any beneficial
owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor
any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time
of sale of the securities in the Offering and/or at the Effective Time (each, a "Company Covered Person" and, together,
"Company Covered Persons") is subject to a Disqualification Event (as defined below), except for a Disqualification Event
covered by Rule 506(d)(2) or (d)(3) or has been involved in any matter that would be a Disqualification Event except for the fact
that it occurred before September 23, 2013. The Company has exercised reasonable care to determine whether any Company Covered
Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations
under Rule 506(e), and has furnished to the Company a copy of any disclosures provided thereunder.

 

(s)            Placement
Agent’s Fees. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory
fees, or brokers’ commissions (other than for Persons engaged by any Buyer or its investment advisor), escrow agent fees
or legal fees incurred by the Company relating to or arising out of the transactions contemplated hereby, (including, without limitation,
any fees payable to the placement agent, Katalyst Securities LLC (the “Placement Agent”)), as outlined in Section
3(s) of the Disclosure Schedule (such warrants on Schedule 3(s) to be issued to the Placement Agent, the “Placement
Agent Warrants”).

 

(t)            No
Integrated Offering. Other than the consent of the majority of the Holders of the Series B Shares, none of the Company, its
Subsidiaries or any of their Affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to require approval of stockholders of the Company under any applicable stockholder approval provisions, including, without limitation,
under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are
listed or designated for quotation. No registration of the offer, sale or transfer of any of the Securities is required, except
for registration contemplated hereby pursuant to the Registration Rights Agreement.

 

    	 	- 12 -	 

     

    

 

4.            COVENANTS.

 

(a)           Reporting
Status. Until the date that is five years from the Initial Closing (the “Reporting Period”), the Company
shall file all reports required to be filed with the SEC pursuant to the 1934 Act and the Company shall not terminate its status
as an issuer required to file reports pursuant to the 1934 Act (even if the 1934 Act or the rules and regulations thereunder would
no longer require or otherwise permit such termination).

 

(b)           Quotation/Listing.
The Company’s Common Stock is currently designated for quotation on the pink sheets maintained by the OTC Markets Group,
Inc. (an “Eligible Market”, which term may also include, if applicable, the OTCQX marketplace of the OTC Markets
Group, Inc., the OTCQB marketplace of the OTC Markets Group, Inc., The New York Stock Exchange, the NYSE MKT, the Nasdaq Global
Market, the Nasdaq Capital Market or the Nasdaq Global Select Market.

 

(c)           Fees.
The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable
attorneys’ fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment, including,
but not limited to, expenses in Section 3(s). Except as otherwise set forth in the Transaction Documents, each party to this Agreement
shall bear its own expenses in connection with the sale of the Securities to the Buyers.

 

(d)           Disclosure
of Transactions and Other Material Information. The Company shall, on or before 9:30 a.m., New York time, on or before the
fourth Business Day following each Closing, issue a press release (the “Press Release”) disclosing all the material
terms of the transactions contemplated by the Transaction Documents. On or before 5:30 p.m., New York time, on or before the fourth
Business Day following the date hereof, the Company shall file a Current Report on Form 8-K describing all the material terms of
the transactions contemplated by the Transaction Documents in the form required by the 1934 Act and attaching all the material
Transaction Documents (including, without limitation, this Agreement) (including all attachments, the “8-K Filing”).
Notwithstanding the foregoing, the Company shall not be required to disclose the name of the Placement Agent, or file any exhibits
relating to the Placement Agent, until after the final closing of the offering. From and after the issuance of the Press Release
and the 8-K Filing, the Company shall have disclosed all material, non-public information (if any) delivered to any of the Buyers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents. In addition, effective
after the issuance of the Press Release and the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates
(other than the Buyers set out in Schedule 4(d)), on the other hand, shall terminate with respect to any future disclosure that
are made by or on behalf of the Company. In addition, each of the Buyers set out in Schedule 4(d) acknowledges and agrees that
any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its
Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and such Buyer set
out in Schedule 4(d) or any of their affiliates, on the other hand, shall continue before and after the issuance of the Press Release,
pursuant to the terms of such agreement. The Company shall not, and the Company shall not knowingly allow any of its Subsidiaries
and each of its and their respective officers, directors, employees and agents, to, provide any Buyer with any material, non-public
information regarding the Company or any of its Subsidiaries from and after the date hereof without the express prior written consent
of such Buyer. If a Buyer has, or believes it has, received any such material, nonpublic information regarding the Company or any
of its Subsidiaries from the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees
or agents, it may provide the Company with written notice thereof. The Company shall, within two (2) Trading Days of receipt of
such notice, make public disclosure of such material, nonpublic information. In the event of a breach of any of the foregoing covenants
by the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees and agents (as determined
in the reasonable good faith judgment of such Buyer), in addition to any other remedy provided herein or in the Transaction Documents,
such Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise,
of such material, non-public information without the prior approval by the Company, any of its Subsidiaries, or any of its or their
respective officers, directors, employees or agents. No Buyer shall have any liability to the Company, any of its Subsidiaries,
or any of its or their respective officers, directors, employees, stockholders or agents, for any such disclosure. To the extent
that the Company delivers any material, non-public information to a Buyer without such Buyer's consent, the Company hereby covenants
and agrees that such Buyer shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, affiliates or agents with respect to, or a duty not to trade on the basis of, such material, non-public
information. Subject to the foregoing, neither the Company, its Subsidiaries nor any Buyer shall issue any press releases or any
other public statements with respect to the transactions contemplated hereby without the prior approval of legal counsel; provided,
however, the Company shall be entitled, without the prior approval of any Buyer, to make any press release or other public disclosure
with respect to such transactions (i) in substantial conformity with the Press Release and the 8-K Filing, or any other filing
approved in accordance herewith, and (ii) in the opinion of the Company’s legal counsel, as is required by applicable law
and regulations, or the applicable Eligible Market on which the Company’s common stock is listed or designated. Unless required
by applicable law, without the prior written consent of the applicable Buyer, the Company shall not (and shall not Knowingly allow
any of its Subsidiaries and Affiliates to) disclose the name of such Buyer in any filing (other than in the Transaction Documents
filed as exhibits to the 8-K Filing), announcement, release or otherwise. Notwithstanding anything herein to the contrary except
where otherwise set out, the term “Buyer” or “Buyers” in this Section 4(f) shall exclude the Placement
Agent and any officer, director or employee of the Placement Agent or the Company, or of any of their Subsidiaries.

 

    	 	- 13 -	 

     

    

 

(e)           Use
of Proceeds. The Company shall use the proceeds from the sale of the Securities as set out in the Transaction Documents.

 

(f)            Form
D and Blue Sky. The Company agrees to file a Form D with respect
to the Securities as required under Regulation D and to provide a copy thereof to each of SOVR and counsel to the Placement Agent,
promptly after such filing. The Company shall, on or before each Closing Date, take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Buyers at each Closing
pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to
obtain an exemption from such qualification). The Company shall make all filings and reports relating to the offer and sale of
the Securities required under applicable securities or “Blue Sky” laws of the states of the United States following
each Closing Date at the expense of the Company.

 

(h)           Reverse
Stock Split. As soon as possible after the Effective Time, but in no event later than 90 calendar days from the Effective Time,
the Parent shall (i) enact the Reverse Stock Split and (ii) amend its certificate of incorporation to reduce the number of shares
of issued and outstanding common stock (“Authorized Decrease”). Parent shall make all filings and take all steps required
by the SEC, GCL and FINRA to enact the Reverse Stock Split and the Authorized Decrease.

 

    	 	- 14 -	 

     

    

 

(i)            Registration
Rights. Promptly, but no later than 120 calendar days from the final Closing of the Offering, the Company shall file a registration
statement (on Form S-1, or similar form) with the SEC covering the resale of the shares of Common Stock underlying the Series
B Preferred Stock sold in the Offering and the Common Stock underlying the Placement Agent Warrants, (the “Registration
Statement”). The Company shall use its best efforts to ensure that the Registration Statement is declared effective
within 90 calendar days after filing with the SEC. The Company shall keep the Registration Statement “evergreen” for
one (1) year from the date it is declared effective by the SEC or until Rule 144 of the Securities Act is available to all of
the investors purchasing Securities under this Agreement with respect to all of their Underlying Common Stock, whichever is earlier.

 

5.            REGISTER;
TRANSFER AGENT INSTRUCTIONS; LEGEND.

 

(a)            Register.
The Company’s Transfer Agent shall maintain a register for the Series B Shares and the Common Stock in which the Company
shall record (i) the name and address of the Person in whose name the Series B Shares have been issued (including the name and
address of each transferee), (ii) the number of Series B Shares held by such Person, (iii) the name and address of the Person in
whose name Common Stock is issued upon conversion of the Series B Shares (including the name and address of each transferee), and
(iv) the number of shares of Common Stock held by such Person. Upon reasonable request, the Company shall keep (or instruct the
Transfer Agent to keep) the register open and available at all times during business hours for inspection of any Buyer or its legal
representatives.

 

(b)           Legends.
Each Buyer understands that the Securities have been issued (or will be issued in the case of the underlying Common Stock) pursuant
to an exemption from registration or qualification under the 1933 Act and applicable state securities laws, and except as set forth
below, any certificate representing such Securities shall bear any legend as required by the “blue sky” laws of any
state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of
such stock certificates):

 

NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER, THE SUBSTANCE OF WHICH IS REASONABLY ACCEPTABLE TO THE COMPANY,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER
SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

    	 	- 15 -	 

     

    

 

(c)           Removal
of Legends. Certificates evidencing Securities shall not be required to contain the legend set forth in Section 5(b) above
or any other legend (i) while a registration statement (including a Registration Statement) covering the resale of such Securities
is effective under the 1933 Act, (ii) following any sale of such Securities pursuant to Rule 144 (assuming the transferor is not
an affiliate of the Company), (iii) in connection with a sale, assignment or other transfer (other than under Rule 144), provided
that such Buyer provides the Company with an opinion of counsel to such Buyer, in a generally acceptable substance, to the effect
that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements of
the 1933 Act or (iv) if such legend is not required under applicable requirements of the 1933 Act (including, without limitation,
controlling judicial interpretations and pronouncements issued by the SEC). If a legend is not required pursuant to the foregoing,
the Company shall no later than two (2) Trading Days (as defined below) following the delivery by a Buyer to the Company or the
Transfer Agent (with notice to the Company) of a legended certificate representing such Securities (endorsed or with stock powers
attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together
with any other deliveries from such Buyer as may be required above in this Section, as directed by such Buyer, either: (A) provided
that the Company’s Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program and such Securities
are Common Stock, credit the aggregate number of shares of Common Stock to which such Buyer shall be entitled to such Buyer’s
or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Company’s
Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable overnight
courier) to such Buyer, a certificate representing such Securities that is free from all restrictive and other legends, registered
in the name of such Buyer or its designee (the date by which such credit is so required to be made to the balance account of such
Buyer’s or such Buyer’s nominee with DTC or such certificate is required to be delivered to such Buyer pursuant to
the foregoing is referred to herein as the “Required Delivery Date”). “Trading Day” means,
as applicable, (x) with respect to all price determinations relating to the Common Stock, any day on which the Common Stock is
traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the
principal securities exchange or securities market on which the Common Stock is then traded, provided that “Trading Day”
shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or
any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such
exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending
at 4:00:00 p.m., New York time) or (y) with respect to all determinations other than price determinations relating to the Common
Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities.

 

(d)           Failure
to Timely Deliver; Buy-In. If the Company fails to (i) issue and deliver (or cause to be delivered) to a Buyer by the Required
Delivery Date a certificate representing the Securities so delivered to the Company by such Buyer that is free from all restrictive
and other legends or (ii) following registration on a Registration Statement, credit the balance account of such Buyer’s
or such Buyer’s nominee with DTC for such number of Securities so delivered to the Company, then, in addition to all other
remedies available to such Buyer, the Company shall, within three (3) Trading Days after such Buyer’s request and in such
Buyer’s sole discretion, either (i) pay cash to such Buyer in an amount equal to such Buyer’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”),
at which point the Company’s obligation to deliver such certificate or credit such Buyer’s balance account shall terminate
and such shares shall be cancelled, or (ii) promptly honor its obligation to deliver to such Buyer a certificate or certificates
or credit such Buyer’s DTC account representing such number of shares of Common Stock that would have been issued if the
Company timely complied with its obligations hereunder and pay cash to such Buyer in an amount equal to the excess (if any) of
the Buy-In Price over the product of (A) such number of shares of Underlying Common Stock that the Company was required to deliver
to such Buyer by the Required Delivery Date times (B) the closing bid price of the Common Stock on the Eligible Market on which
the Common Stock principally trades on the Trading Day immediately preceding the Required Delivery Date.

 

6.            CONDITIONS
TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

(a)           The
obligation of each Buyer hereunder to purchase its applicable Series B Shares at each Closing is subject to the satisfaction, at
or before each Closing Date and in respect of each Closing Date (except as otherwise provided herein), of each of the following
conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by such Buyer at any time
in its sole discretion by providing the Company with prior written notice thereof:

 

    	 	- 16 -	 

     

    

 

(i)             The
Company shall have duly executed and delivered to such Buyer each of the Transaction Documents to which it is a party.

 

(ii)            The
Company shall provide to Barbara J. Glenns, legal counsel to the Placement Agent (“Ms. Glenns”) and any Buyer
who so requests beforehand, satisfactory evidence from the Secretary of State of its jurisdiction of formation that the Company
has been formed and is in good standing.

 

(iii)          The
Company shall have delivered to Ms. Glenns and any Buyer who so requests beforehand, a copy of a certificate evidencing the Company’s
qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction
in which the Company is qualified to conduct business at the Initial Closing.

 

(iv)          The
Company shall have delivered to Ms. Glenns and any Buyer who so requests beforehand, a copy of a certified copy of the true and
correct Certificate of Incorporation as of the date within thirty (30) days of the Initial Closing Date.

 

(v)           The
Company shall have delivered to Ms. Glenns and any Buyer who so requests beforehand, a copy of a certificate, in the form reasonably
acceptable to such Buyer, executed by the Secretary of the Company and dated as of the Initial Closing Date, as to (i) the resolutions
approving the Transaction Documents as adopted by the Company’s board of directors in a form reasonably acceptable to such
Buyer, (ii) Certificate of Incorporation, and (iii) the Bylaws of the Company, in each case, as in effect at the Initial Closing.

 

(vi)          Each
and every representation and warranty of the Company shall be true and correct in all material respects as of the date when made
and as of the respective Closing Date as though originally made at that time (except that (1) representations and warranties that
speak as of a specific date shall be true and correct in all material respects as of such date and (2) representations and warranties
that are qualified by material, Material Adverse Effect or other similar materiality qualifiers shall be true and correct in all
respects) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements
and conditions required to be performed, satisfied or complied with by the Company at or prior to respective Closing Date, including,
without limitation the issuance of all Securities prior to the date of such Closing as required by the Transaction Documents and
the Company has a sufficient number of duly authorized shares of Common Stock reserved for issuance as may be required to fulfill
its obligations pursuant to the Transaction Documents. Such Buyer shall have received a certificate, executed by an executive officer
of the Company, dated as of the Initial Closing Date, to the foregoing effect.

 

(vii)         The
statements in the Transaction Documents regarding the Company shall be true and correct in all material respects as of the date
when made. Such Buyer shall have received a certificate, executed by an executive officer of the Company, dated as of the Initial
Closing Date, to the foregoing effect.

 

(viii)        The
statements in the Transaction Documents regarding PTI shall be true and correct in all material respects as of the date when made.
Such Buyer shall have received a certificate, executed by an executive officer of PTI, dated as of the Initial Closing Date, to
the foregoing effect.

 

    	 	- 17 -	 

     

    

 

(ix)           The
Company shall have delivered to Ms. Glenns and any Buyer who so requests beforehand, a report from the Company’s Transfer
Agent identifying the number of shares of Common Stock and Series B Shares outstanding on the Trading Day immediately prior to
the Initial Closing.

 

(x)            The
Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale
of the Securities.

 

(xi)           No
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents, and no actions, suits or proceedings shall be in progress or pending by any Person that seeks to
enjoin, prohibit or otherwise adversely affect any of the transactions contemplated by the Transaction Documents.

 

(xii)          Since
the date of execution of this Agreement, no event or series of events shall have occurred that reasonably would have or result
in a Material Adverse Effect and the Company has not filed for nor is it subject to any bankruptcy, insolvency, reorganization
or liquidation proceedings or other proceedings for relief under any bankruptcy law or any law for the relief of debtors instituted
by or against the Company.

 

(xiii)         The
Company shall have delivered to Ms. Glenns, such other documents, instruments or certificates relating to the transactions contemplated
by this Agreement reasonably required to consummate the transactions contemplated hereby.

 

(xiv)        The
Certificate of Designations has been filed with the Secretary of State of Delaware, and a copy thereof time-stamped by the Delaware
Secretary of State has been delivered to the Buyer.

 

(xv)          If
the Initial Closing, the Company has received executed Securities Purchase Agreements to close on at least the Minimum Offering.

 

(xvi)         If
the Initial Closing, the Merger shall occur simultaneously with the Initial Closing.

 

(b)           The
obligation of the Company hereunder to sell its applicable Series B Shares at each Closing to any Buyer is subject to the satisfaction,
at or before each Closing Date and in respect of each Closing Date (except as otherwise provided herein), of each of the following
conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time
in its sole discretion by providing such Buyer with prior written notice thereof:

 

(i)            Such
Buyer shall have duly executed and delivered to the Company each of the Transaction Documents to which it is a party.

 

(ii)           If
such Buyer is a party to the Escrow Agreement, such Buyer has complied with the terms of the Escrow Agreement applicable to such
Buyer.

 

(iii)          If
the Initial Closing, the Company has received executed Securities Purchase Agreements to close on at least the Minimum Offering.

 

    	 	- 18 -	 

     

    

 

(iv)          Such
Buyer shall have delivered to the Company, such other documents, instruments or certificates relating to the transactions contemplated
by this Agreement reasonably required to consummate the transactions contemplated hereby.

 

7.            [Intentionally
Omitted]

 

8.            MISCELLANEOUS.

 

(a)           Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall (i)
limit or be deemed to limit in any way any right to serve process in any manner permitted by law or (ii) operate, or be deemed
to operate, to preclude any Buyer from bringing suit or taking other legal action against the Company in any other jurisdiction
to collect on the Company’s obligations to such Buyer or to enforce a judgment or other court ruling in favor of such Buyer
or (iii) limit, or be deemed to limit, any provision of the Certificate of Designations which is contrary to the above. EACH PARTY
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(b)           Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an
executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

(c)           Headings;
Gender; Certain Meanings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect
the interpretation of, this being deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms
“including,” “includes,” “include” and words of like import shall be construed broadly as if
followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof”
and words of like import refer to this entire Agreement instead of just the provision in which they are found. When used herein,
the words “law,” “rule,” “regulation” and the like means all applicable laws, rules and regulations,
domestic or foreign, state, provincial, local or self-regulatory, including without limitation as to all applicable laws, rules
and regulations of or related to the United States, applicable states, the SEC, and the Principal Market.

 

    	 	- 19 -	 

     

    

 

(d)           Severability.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(e)           Entire
Agreement; Amendments. Except with regards to any confidentiality or non-disclosure agreement entered into between the Buyers,
the Company, their Affiliates and Persons acting on their behalf in connection with the transactions contemplated hereunder, this
Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and thereto and the instruments referenced
herein and therein supersede all other prior oral or written agreements between the Buyers, the Company, their Affiliates and Persons
acting on their behalf solely with respect to the matters contained herein and therein, and this Agreement, the other Transaction
Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein contain the
entire understanding of the parties solely with respect to the matters covered herein and therein; provided, however, nothing contained
in this Agreement or any other Transaction Document shall (or shall be deemed to), (i) have any effect on any agreements any Buyer
has entered into with the Company or any of its Subsidiaries prior to the date hereof with respect to any prior investment made
by such Buyer in the Company or (ii) waive, alter, modify or amend in any respect any obligations of the Company or any of its
Subsidiaries, or any rights of or benefits to any Buyer or any other Person, in any agreement entered into prior to the date hereof
between or among the Company and/or any of its Subsidiaries and any Buyer and all such agreements shall continue in full force
and effect. Except as specifically set forth herein or therein, neither the Company nor any Buyer makes any representation, warranty,
covenant or undertaking with respect to such matters. For clarification purposes, the Recitals are part of this Agreement. No provision
of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment,
by (i) the Company and (ii) the Buyers who own at least 66% of the Series B Shares purchase hereunder,
and in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; provided, that
if any amendment, modification or waiver disproportionately and adversely impacts a Buyer, the consent of such Buyer shall also
be required. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.
Any amendment or waiver effected in accordance with this Section shall be binding upon each Buyer. No such amendment shall be effective
to the extent that it applies to less than all of the Buyers. No consideration shall be offered or paid to any Person to amend
or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration also
is offered to all of the parties to the Transaction Documents.

 

(f)           Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); (iii) when sent, if sent by e-mail (provided that such sent e-mail is kept on file (whether electronically or otherwise)
by the sending party and the sending party does not receive an automatically generated message from the recipient’s e-mail
server that such e-mail could not be delivered to such recipient); and (iv) one (1) Business Day after deposit with an overnight
courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. The addresses
and facsimile numbers and email addresses for such communications shall be:

 

    	 	- 20 -	 

     

    

 

If to the Company or the Parent (subsequent to the
Initial Closing):

 

Protagenic Therapeutics, Inc.

149 Fifth Avenue, Suite 500

New York, NY 10010

Attn: Robert Ziroyan, President

Facsimile: 508.734.2177

Email: rziroyan@protagenic.com

 

If to the Parent or the Acquisition Subsidiary (prior
to the Initial Closing):

 

Atrinsic, Inc.

65 Atlantic Avenue

Boston, Massachusetts 02110

Attn:  Edward Gildea, Chief Executive Officer

Facsimile: (508) 744-3777

Email: edward.gildea@fisherbroyles.com

 

If to a Buyer, to its address and facsimile
number set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Buyer’s
signature page.

 

Notice shall be sent to such other address
and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written notice given
to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient
of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile
machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided
by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight
courier service in accordance with clause (i), (ii) or (iii) above, respectively. A copy of the e-mail transmission containing
the time, date and recipient e-mail address shall be rebuttable evidence of receipt by e-mail in accordance with clause (iii) above.

 

(g)           Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns, including, as contemplated below, any assignee of any of the Securities. The Company shall not assign this Agreement or
any rights or obligations hereunder without the prior written consent of each of the Buyers. A Buyer may assign some or all of
its rights hereunder in connection with any transfer of any of its Securities without the consent of the Company, in which event
such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights.

 

(h)           No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than
the Buyer Indemnitees referred to in Section 8(k).

 

(i)            Survival.
The representations, warranties, agreements and covenants shall survive each Closing. Each Buyer shall be responsible only for
its own representations, warranties, agreements and covenants hereunder.

 

    	 	- 21 -	 

     

    

 

(j)            Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

(k)           Indemnification.
The Buyer agrees to indemnify and hold harmless the Company, the Placement Agent (including its selected dealers, if any), and
their respective officers, directors, employees, agents, control persons and affiliates from and against all losses, liabilities,
claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating,
preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false
acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Buyer of
any covenant or agreement made by the Buyer herein or in any other document delivered in connection with this Agreement.

 

(l)            Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and
no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality
or applicability of a more general representation or warranty. Each and every reference to share prices, shares of Common Stock
and any other numbers in this Agreement that relate to the Common Stock shall be automatically adjusted for stock splits, stock
combinations and other similar transactions that occur with respect to the Common Stock after the date of this Agreement.

 

(m)          Remedies.
Each Buyer and each holder of any Securities shall have all rights and remedies set forth in the Transaction Documents and all
rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights
which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to
enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any
provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event
that it fails to perform, observe, or discharge any or all of its obligations under the Transaction Documents, any remedy at law
may prove to be inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to seek specific
performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction
in any such case without the necessity of proving actual damages and without posting a bond or other security.

 

    	 	- 22 -	 

     

    

 

(n)           Independent
Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under the Transaction Documents are several and
not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations
of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action
taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the
Buyers do not so constitute, a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption
that the Buyers are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated
by the Transaction Documents or any matters, and the Company acknowledges that the Buyers are not acting in concert or as a group,
and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated by the Transaction
Documents. The decision of each Buyer to purchase Securities pursuant to the Transaction Documents has been made by such Buyer
independently of any other Buyer. Each Buyer acknowledges that no other Buyer has acted as agent for such Buyer in connection with
such Buyer making its investment hereunder and that no other Buyer will be acting as agent of such Buyer in connection with monitoring
such Buyer’s investment in the Securities or enforcing its rights under the Transaction Documents. The Company and each Buyer
confirms that each Buyer has independently participated with the Company in the negotiation of the transaction contemplated hereby
with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall
not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose. The use of a single
agreement to effectuate the purchase and sale of the Securities contemplated hereby was solely in the control of the Company, not
the action or decision of any Buyer, and was done solely for the convenience of the Company and not because it was required or
requested to do so by any Buyer. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Buyer, solely, and not between the Company and the Buyers collectively
and not between and among the Buyers.

 

(o)          Potential
Conflicts. The Placement Agent, its subagents, employees, legal counsel and/or their respective Affiliates, principals,
representatives or employees may now or hereafter own shares of the Company.

 

[signature page follows]

 

    	 	- 23 -	 

     

    

 

IN WITNESS WHEREOF, Buyer and the
Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	ATRINSIC, INC.
	 	 
	 	By:	 
	 	 	Name:	 	  
	 	 	Title:	 	 

 

[BUYER SIGNATURE PAGE FOLLOWS]

 

    	 	- 24 -	 

     

    

 

ATRINSIC, INC.

OMNIBUS SIGNATURE PAGE TO

SECURITIES PURCHASE
AGREEMENT AND REGISTRATION RIGHTS AGREEMENT

 

The undersigned, desiring to: (i) enter
into the Securities Purchase Agreement, dated as of ____________ ___, 20161
(the “Securities Purchase Agreement”), between the undersigned, Atrinsic, Inc. a Delaware corporation (the “Company”),
and the other parties thereto, in or substantially in the form furnished to the undersigned, (ii) enter into the Registration Rights
Agreement (the “Registration Rights Agreement”) among the undersigned, the Company and the other parties thereto, in
or substantially in the form furnished to the undersigned and (iii) purchase Series B Shares as set forth in the Securities Purchase
Agreement and below, hereby agrees to purchase such Series B Shares from the Company and further agrees to join the Securities
Purchase Agreement and the Registration Rights Agreement as a party thereto, with all the rights and privileges appertaining thereto,
and to be bound in all respects by the terms and conditions thereof. The undersigned specifically acknowledges having read the
representations section in the Securities Purchase Agreement entitled “Buyer’s Representations and Warranties”
and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Buyer.

 

IN WITNESS WHEREOF, the Purchaser hereby
executes the Securities Purchase Agreement and the Registration Rights Agreement:

 

Dated: ________________ , 2016

 

	 	X	 	$1.25	 	=	$
	Number of Series B Shares	 	Purchase Price per Share	 	Total Purchase Price

 

 

	PURCHASER (individual)	 	PURCHASER (entity)
	 	 	 
	 	 	 
	Signature	 	Name of Entity
	 	 	 
	 	 	 
	Print Name	 	Signature
	 	 	 
	 	 	Print Name:	 
	Signature (if Joint Tenants or Tenants in Common)	 	Title:	 

 

	Address of Principal Residence:	 	Address of Executive Offices:
	 	 	 
	 	 	 
	 	 	 

 

 

1
Will reflect the Closing Date. Not to be completed by Buyer.

 

    	 	- 25 -	 

     

    

 

	Social Security Number(s):	 	IRS Tax Identification Number:
	 	 	 
	 	 	 
	Telephone Number: 	                                  	 	Telephone Number: 	                                   
	Facsimile Number:	 	 	Facsimile Number:	 
	E-mail Address:	 	 	E-mail Address:	 

 

 

Will reflect the Closing Date. Not to be completed by
Purchaser.

 

    	 	- 26 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}]]